At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
IMMX Immix Biopharma, Inc.
Closed 12-11 16:00:00 EST
7.38
+0.65
+9.66%
盘后7.26
-0.12-1.63%
19:49 EST
High7.45Low6.61Vol1.97M
Open6.82D1 Closing6.73Amplitude12.41%
Mkt Cap384.89MTradable Cap305.82MTotal Shares52.15M
T/O13.99MT/O Rate4.75%Tradable Shares41.44M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Immix Biopharma CEO Ilya Rachman Acquires Common Shares
Reuters  ·  12-11 07:49
Immix Biopharma CEO Ilya Rachman Acquires Common Shares
Immix Biopharma CFO Gabriel S. Morris Reports Acquisition of Common Shares
Reuters  ·  12-11 07:47
Immix Biopharma CFO Gabriel S. Morris Reports Acquisition of Common Shares
BRIEF-Immix Biopharma Announces Closing Of Upsized $100 Million Underwritten Offering Of Common Stock And Pre-Funded Warrants
Reuters  ·  12-10 06:52
BRIEF-Immix Biopharma Announces Closing Of Upsized $100 Million Underwritten Offering Of Common Stock And Pre-Funded Warrants
Immix Biopharma Is Maintained at Buy by HC Wainwright & Co.
Dow Jones  ·  12-09 23:42
Immix Biopharma Is Maintained at Buy by HC Wainwright & Co.
Immix Biopharma, Inc. : H.c. Wainwright Raises Target Price to $12 From $8
THOMSON REUTERS  ·  12-09 21:25
Immix Biopharma, Inc. : H.c. Wainwright Raises Target Price to $12 From $8
Immix Biopharma Inc. unveils presentation on relapsed/refractory AL amyloidosis treatment challenges
Reuters  ·  12-09
Immix Biopharma Inc. unveils presentation on relapsed/refractory AL amyloidosis treatment challenges
BRIEF-Immix Biopharma Prices Offering Of 19.1 Million Shares At $5.10 Per Share
Reuters  ·  12-08
BRIEF-Immix Biopharma Prices Offering Of 19.1 Million Shares At $5.10 Per Share
Immix Biopharma Announces Pricing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
THOMSON REUTERS  ·  12-08
Immix Biopharma Announces Pricing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
Immix Biopharma Inc - Prices Offering of 19.12 Mln Shares at $5.10 per Share
THOMSON REUTERS  ·  12-08
Immix Biopharma Inc - Prices Offering of 19.12 Mln Shares at $5.10 per Share
Immix Biopharma Reports 75% Complete Response Rate in Phase 2 NXC-201 Trial for Relapsed/Refractory AL Amyloidosis
Reuters  ·  12-08
Immix Biopharma Reports 75% Complete Response Rate in Phase 2 NXC-201 Trial for Relapsed/Refractory AL Amyloidosis
at Ash 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 Nxc-201 Results, Advancing Toward Bla Submission as a Potentially First- and Best-in-Class Therapy for Relapsed/Refractory Al Amyloidosis
THOMSON REUTERS  ·  12-08
at Ash 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 Nxc-201 Results, Advancing Toward Bla Submission as a Potentially First- and Best-in-Class Therapy for Relapsed/Refractory Al Amyloidosis
Immix Biopharma Unveils Breakthrough Strategy for Relapsed/Refractory AL Amyloidosis
Reuters  ·  12-03
Immix Biopharma Unveils Breakthrough Strategy for Relapsed/Refractory AL Amyloidosis
Immix Biopharma Appoints Michael Grabow as Chief Commercial Officer
Reuters  ·  11-12
Immix Biopharma Appoints Michael Grabow as Chief Commercial Officer
Immix Biopharma Appoints Chief Commercial Officer to Drive Nxc-201 Launch
THOMSON REUTERS  ·  11-12
Immix Biopharma Appoints Chief Commercial Officer to Drive Nxc-201 Launch
Immix Biopharma Inc expected to post a loss of 17 cents a share - Earnings Preview
Reuters  ·  11-08
Immix Biopharma Inc expected to post a loss of 17 cents a share - Earnings Preview
Immix Biopharma Unveils Breakthrough Approach for Relapsed AL Amyloidosis Treatment
Reuters  ·  11-04
Immix Biopharma Unveils Breakthrough Approach for Relapsed AL Amyloidosis Treatment
Immix Biopharma to Present Phase 1/2 NXC-201 CAR-T Trial Results for AL Amyloidosis at ASH 2025
Reuters  ·  11-03
Immix Biopharma to Present Phase 1/2 NXC-201 CAR-T Trial Results for AL Amyloidosis at ASH 2025
Immix Biopharma’s Nxc-201 Nexicart-2 Clinical Trial Results Selected for Oral Presentation at Ash 2025
THOMSON REUTERS  ·  11-03
Immix Biopharma’s Nxc-201 Nexicart-2 Clinical Trial Results Selected for Oral Presentation at Ash 2025
Immix Biopharma Inc. to Present at Guggenheim Healthcare Innovation Conference
Reuters  ·  10-14
Immix Biopharma Inc. to Present at Guggenheim Healthcare Innovation Conference
Immix Biopharma Inc publishes presentation highlighting leadership in relapsed and refractory AL Amyloidosis and promising NXC201 clinical data
Reuters  ·  10-09
Immix Biopharma Inc publishes presentation highlighting leadership in relapsed and refractory AL Amyloidosis and promising NXC201 clinical data

Introduction

Company Name.
Immix Biopharma, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and immune-dysregulated diseases in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and colorectal cancer; and NXC-201 for relapsed/refractory multiple myeloma. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.
Issue price:
--